22 February 2018 - - Petach Tikva, Israel-based generic and specialty medicines company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has made the QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol commercially available by prescription to patients in both 40 mcg and 80 mcg strengths in the US, the company said.
QVAR RediHaler is a breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients four years of age and older. It is not indicated for the relief of acute bronchospasm.
The QVAR RediHaler delivers medication via a breath-actuated inhaler, eliminating the need for hand-breath coordination during inhalation. It administers the same active ingredient found in the previously available QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated inhaler technology.
QVAR RediHaler was also designed to be ready for use, with no shaking or priming needed. Because the medication delivery is breath actuated, it should not be used with a spacer or volume holding chamber.
Teva is a patient-centric healthcare solutions, and generic and specialty medicines producer. It leverages its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.
In specialty medicines, the company has an innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a portfolio of respiratory products.